You are here

Recent Pfizer Press Releases

4/21/17 8:36am EDT
Pfizer Unveils ATLAS, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries

ATLAS Is Designed To Help Physicians Select Appropriate Antibiotics For Their Patients And Responds To The Need For Mobile Resources At The Point Of Care

ATLAS Can Also Help Inform Global Health Strategies To Mitigate The Threat Of Antimicrobial Resistance (AMR)

Pfizer Inc. today announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries. Understanding evolving bacterial resistance patterns is a key element in managing the rise of antimicrobial resistance.

more...
4/20/17 3:00pm EDT
Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.m. (Eastern Daylight Time) on Thursday, April 27, 2017.

more...
4/20/17 9:00am EDT
PSI And Pfizer Partner To Address Hypertension In Vietnam And Myanmar

The international nonprofit organization Population Services International (PSI) and the biopharmaceutical company Pfizer Inc. (NYSE:PFE) today announced Healthy Communities, a US $1 million collaboration to expand access to life-saving hypertension medicines and treatment services in Myanmar and Vietnam.

more...
3/27/17 5:00am EDT
3/24/17 10:18am EDT
Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease

TRUMENBA Has Been Studied in a Global Clinical Development Program Evaluating the Vaccine in Adolescents and Adults1

The Majority of Meningococcal Disease Cases in Europe are Caused by Meningococcal Group B (MenB), with Adolescents and Young Adults at Increased Risk2

Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that TRUMENBA® (Meningococcal Group B Vaccine) be granted marketing authorization in the European Union (EU) for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB).3 The CHMP’s opinion will now be sent to the European Commission (EC) for final decision.

more...
3/23/17 5:30pm EDT
FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

  • Only FDA-approved treatment for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer  
  • First indication for BAVENCIO, a human anti-PD-L1 antibody 

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC). This indication is approved under accelerated approval based on tumor response and duration of response.

more...
3/23/17 4:20pm EDT
FDA Grants Approval for BAVENCIO® (avelumab)

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announce that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection 20 mg/mL, for intravenous use. 

The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.

more...
3/22/17 10:30am EDT
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2017 Performance Report, to be issued that morning.

more...
3/17/17 11:15am EDT
Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation

In this U.S. Medicare database analysis, Eliquis® (apixaban) was associated with significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin

3/15/17 8:00pm EST
Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis

 

 

Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its oral Janus kinase (JAK) inhibitor, XELJANZ

more...
3/9/17 2:00am EST
Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

Servier, together with Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), announced today that the U.S. Food and Drug Administration (FDA) has granted Servier with an Investigational New Drug (IND) clearance to proceed in the U.S. with the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia.

more...
3/8/17 8:00am EST
The Union for International Cancer Control and Pfizer Announce Next Phase of Global Grants Initiative Supporting Metastatic Breast Cancer Patients

Pfizer Commits Funding to Continue SPARC MBC Challenge Grants Partnership with UICC Bringing Total Funding to More Than $1.3 Million (USD)

In conjunction with International Women’s Day, The Union for International Cancer Control (UICC) and Pfizer Inc. today announced the next phase of their pioneering grants initiative to address the unique challenges facing metastatic breast cancer (mBC) patients around the globe. The Seeding Progress and Resources for the Cancer Community (SPARC): Metastatic Breast Cancer Challenge was designed to support the implementation of projects that address the specific needs of women with metastatic breast cancer globally - many of which extend beyond treatment.

more...
3/6/17 8:30am EST
Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

  • Post-hoc Analyses from the ARISTOTLE Trial Featured in Late-Breaker and Poster Sessions 
  • Real-World Data Analyses Include Database Reviews of U.S. Medicare Patient Population 

3/6/17 8:00am EST
Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or Metformin 

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes: one for monotherapy, one for the fixed-dose combination of ertugliflozin and JANUVIA® (sitagliptin), and one for the fixed-dose combination of ertugliflozin and metformin.

more...
2/28/17 6:53pm EST
Pfizer Prices €4,000,000,000 Debt Offering

Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of four tranches of notes:

€1,250,000,000 aggregate principal amount of floating rate notes due 2019

€1,000,000,000 aggregate principal amount of 0.000% notes due 2020

€1,000,000,000 aggregate principal amount of 0.250% notes due 2022

€750,000,000 aggregate principal amount of 1.000% notes due 2027

more...
2/28/17 10:00am EST
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by John Young, Group President, Pfizer Essential Health, at the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 7, 2017 at 11:20 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Cowen and Company 37th Annual Healthcare Conference” link in the For Investors section located on the lower right-hand corner of that page.

more...
2/28/17 7:00am EST
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review

Second Biologics License Application accepted by the FDA for avelumab

Prognosis for urothelial carcinoma is currently poor, particularly when the disease has metastasized

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review EMD Serono's Biologics License Application (BLA) for avelumab* as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 27, 2017, for avelumab in this indication.

more...

Pages